RESUMEN
Twenty-eight patients showing negative responses against Brucella antigens were included in a preliminary trial of immunotherapy by a live Brucella abortus vaccine. Seventeen patients had squamous cell lung carcinoma, eight had acute myeloid leukemia, and three were classified as "others." Brucella abortus strain 19 BA was administered sc in a single injection at doses ranging from 5 X 10(7) viable organisms to 10(10), ie, 40 times the usual vaccine dose. No important toxicity was noted. Edematous reactions at the injection site and febrile responses were infrequent and moderate, hemocultures were all negative, spleen volume did not vary significantly, and cbc showed an increase of polymorphonuclear cells and lymphocytes.
Asunto(s)
Vacuna contra la Brucelosis/uso terapéutico , Carcinoma de Células Escamosas/terapia , Leucemia Mieloide/terapia , Neoplasias Pulmonares/terapia , Recuento de Células Sanguíneas , Temperatura Corporal , Brucella abortus , Estudios de Evaluación como Asunto , Humanos , Inmunoterapia , VacunaciónRESUMEN
This clinical trial of fenspiride (injectable and sustained-release 80 mg tablet) was carried out on patients selected because their bronchopathy was of a hypersecretory type. Interesting results were observed in 20 out of 37 cases, but they were often delayed. This group of patients included a high proportion of patients with major hypersecretion; the efficacy of fenspiride is often evident, (in 8 out of 11 cases) but it is unpredictable individually. It can be concluded from this trial that a long term treatment with fenspiride, well tolerated, can usefully be tried in patients with predominant signs of bronchial hyperexudation.